Collectively, we show that the abundance of STAT2 and of USP18, in combination with information on patient‐specific IFNα levels allow us to propose with our calibrated mathematical model an IFNα treatment regime to prevent pathway desensitization and to optimize an antiviral or anti‐tumor response. The gene discussed is IFNA2; the disease is neoplasm.